In the final analysis of a phase 3 trial published Oct. 22, 2026, in the New England Journal of Medicine, sibeprenlimab kept kidney function stable over 24 months in IgA nephropathy, while it fell on placebo. Kidney events occurred in…
In an interim analysis of a phase 3 trial published Oct. 23, 2026, in the New England Journal of Medicine, ravulizumab lowered urine protein by 46.6% at week 34 in IgA nephropathy, vs. 5.6% with placebo, with no meningococcal infections.
In the final analysis of the ORIGIN 3 trial, published Oct. 22, 2026, in the New England Journal of Medicine, atacicept nearly stopped the yearly loss of kidney function in IgA nephropathy, and kidney disease progression occurred in 5.1% vs.…